FR2795320A1 - Hypotonic injectable solutions for esthetic treatment and for use in cancer treatment - Google Patents
Hypotonic injectable solutions for esthetic treatment and for use in cancer treatment Download PDFInfo
- Publication number
- FR2795320A1 FR2795320A1 FR9908030A FR9908030A FR2795320A1 FR 2795320 A1 FR2795320 A1 FR 2795320A1 FR 9908030 A FR9908030 A FR 9908030A FR 9908030 A FR9908030 A FR 9908030A FR 2795320 A1 FR2795320 A1 FR 2795320A1
- Authority
- FR
- France
- Prior art keywords
- hypotonic
- milliosmol
- treatment
- osmotic pressure
- injectable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 3
- 201000011510 cancer Diseases 0.000 title claims 2
- 238000002347 injection Methods 0.000 claims abstract description 8
- 239000007924 injection Substances 0.000 claims abstract description 8
- 230000006378 damage Effects 0.000 claims abstract description 7
- 239000000243 solution Substances 0.000 claims abstract description 3
- 230000000638 stimulation Effects 0.000 claims abstract description 3
- 210000000577 adipose tissue Anatomy 0.000 claims abstract 3
- 230000003204 osmotic effect Effects 0.000 claims description 9
- 210000003491 skin Anatomy 0.000 claims description 7
- 206010016654 Fibrosis Diseases 0.000 claims description 5
- 230000004761 fibrosis Effects 0.000 claims description 4
- 238000001802 infusion Methods 0.000 claims description 3
- 230000037303 wrinkles Effects 0.000 claims description 3
- 206010015995 Eyelid ptosis Diseases 0.000 claims description 2
- 210000004207 dermis Anatomy 0.000 claims description 2
- 210000004177 elastic tissue Anatomy 0.000 claims description 2
- 210000003780 hair follicle Anatomy 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 201000003004 ptosis Diseases 0.000 claims description 2
- 210000004872 soft tissue Anatomy 0.000 claims description 2
- 229940102223 injectable solution Drugs 0.000 claims 3
- 230000008034 disappearance Effects 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 2
- 210000004209 hair Anatomy 0.000 abstract description 2
- 238000007920 subcutaneous administration Methods 0.000 abstract description 2
- 230000010412 perfusion Effects 0.000 abstract 1
- 238000007665 sagging Methods 0.000 abstract 1
- 230000037394 skin elasticity Effects 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 2
- 239000000815 hypotonic solution Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Indications des solutés hypotoniques et leur mode d'administration en médecine esthétique et cancérologie.. Les indications spécifiques de l'injection hypodermique des solutés hypotoniques sont détaillées apportant une solution là où il n'y en avait pas dans les domaines du relâchement sous cutané, du comblement des dépressions cutanées, de la destruction de tissu graisseux, de l'épilation définitive et de la stimulation de l'élasticité cutanée. Le mode d'administration est détaillé faisant appel à une tubulure de perfusion montée sur aiguille.Indications of hypotonic solutes and their mode of administration in aesthetic medicine and oncology. The specific indications of hypodermic injection of hypotonic solutes are detailed providing a solution where there was none in the areas of subcutaneous sagging, filling of skin depressions, destruction of fatty tissue, permanent hair removal and stimulation of skin elasticity. The mode of administration is detailed using a perfusion tube mounted on a needle.
Description
L'invention ci-dessous concerne la médecine esthétique et la cancérologie. Elle décrira de nouvelles applications au brevet français n 97 14073 ainsi que les moyens techniques mis en oeuvre pour son application. Seront exposés successivement les indications de relachement cutané, fibrose, destruction de tissu y compris les cancers, la destruction des follicules pileux, la stimulation de l'élasticité cutané. The invention below relates to aesthetic medicine and oncology. It will describe new applications to French Patent No. 97 14073 as well as the technical means implemented for its application. Will be exposed successively the indications of skin release, fibrosis, destruction of tissue including cancers, destruction of hair follicles, stimulation of cutaneous elasticity.
<U>Les</U> relachements sous cutanés entrainant une ptose de la peau n'avait aucun traitement jusqu'à présent. La chirurgie permettait de remettre en tension la peau en excisant l'excès et en amarrant l'extrémité sur une structure fixe: tendon ou muscle. Cette technique chirurgicale concentre la tension uniquement sur l'extrémité cutanée provoquant du même coup sa dilatation.`L'injection se pratique de manière oblique sous cutanée de la superficie à la profondeur et du bas vers le haut le segment de membre étant en position anti-gravitationnelle. Le soluté est très hypotonique d'osmolarité strictement inférieure à 18 Mosmoles par litre jusqu'à 1 mosmole par litre. Un tel soluté necessitait d'être injecté avec une grande précision au niveau de la quantité de produit évitant ainsi des réactions cutanées à type de nécrose. l'unique solution a consisté à injecter par l'intermédiaire d'une tubulure de perfusion permettant de compter facilement les gouttes.L'aiguille utilisée est de 0,8Millimètre pour une longueur de 40 à 50 millimètres mais le diamètre peut aller de 0,5 à 1,2 Millimètre et la longueur de 15mm à 50mm. <U> Subcutaneous loosening resulting in ptosis of the skin had no treatment until now. The surgery allowed to re-tension the skin by excising the excess and mooring the end on a fixed structure: tendon or muscle. This surgical technique concentrates the tension only on the cutaneous extremity causing at the same time its dilatation. The injection is practiced obliquely subcutaneously from the surface to the depth and from the bottom to the top the limb segment being in anti -gravitationnelle. The solute is very hypotonic osmolarity strictly less than 18 Mosmoles per liter up to 1 mosmol per liter. Such a solute needed to be injected with great precision in terms of the amount of product thus avoiding skin reactions such as necrosis. the only solution was to inject via an infusion tubing to easily count the drops.The needle used is 0.8Millimeter for a length of 40 to 50 millimeters but the diameter can go from 0, 5 to 1.2 Millimeter and the length from 15mm to 50mm.
Les injections seront réparties sur toute la surface à traiter et provoqueront une micro-fibrose rétractile réactionnelle: L'inflammation extrême déclenchée par les quelques gouttes de soluté entre une et dix stimuleront l'apparition d'un tissu fibreux d'autant plus fin qu'il y aura eu peu de gouttes. The injections will be spread over the entire surface to be treated and will cause a retractile micro-fibrosis reaction: The extreme inflammation triggered by the few drops of solute between one and ten will stimulate the appearance of a fibrous tissue even more thin that there will have been few drops.
Ce tissu est d'une grande fermeté et se retracte en quelques semaines. La peau est alors tirée vers le haut et la mobilité du tissu sous cutané est diminuée. Le soluté est caractérisée par sa pression osmotique quelles que soient les substances dissoutes : électrolytes, acides organiques, lipides, protides, glucides substances chimiques ect.. This fabric is very firm and retracts in a few weeks. The skin is then pulled up and the mobility of the subcutaneous tissue is diminished. The solute is characterized by its osmotic pressure whatever the dissolved substances: electrolytes, organic acids, lipids, proteins, carbohydrates chemical substances ect ..
A titre d'exemple 0,6 milliosmole d'anesthésiant local et glucose sont ajouté à de l'eau pour préparation injectable de manière à obtenir une quantité suffisante pour 250 Millilitre. Une tubulure de perfusion comprenant un goutte à goutte est munie d'une aiguillé de 0,8 millimètre de diamètre et de 50 millimètre de longueur. Le soluté est ainsi injecté avec une précision d'une goutte à raison de une à 10 gouttes de soluté à interval régulier : de 1 à 5 cm entre chaque injection. By way of example, 0.6 milliosmoles of local anesthetic and glucose are added to water for injection so as to obtain a sufficient quantity for 250 milliliters. An infusion tubing comprising a drip is provided with a needle of 0.8 millimeters in diameter and 50 millimeters in length. The solute is thus injected with a precision of one drop at a rate of one to 10 drops of solute at regular intervals: 1 to 5 cm between each injection.
Un hématome se constitue et persiste 15 jours. Les résultats sont manifestent à partir de 7 jours parfois 60. <U>La fibrose</U> proprement dite est induite a pour indication: le comblement des dépressions cutanées et des rides. De multiples substances sont proposées dans le domaine du comblement de rides et une grande partie d'entre elles agissent par fibrose réactionnelle. Le faible coût et l'absence de viscosité du soluté classent les solutés hypotoniques parmi lés produits les plus avantageux. Le soluté possède les même caractéristiques que précédemment et s'injecte à l'aide d'une seringue à insuline et d'une aiguille très fine: 0,3 millimètre. A hematoma is formed and persists for 15 days. The results are manifest from 7 days sometimes 60. <U> The fibrosis </ U> itself is induced for the indication: the filling of cutaneous depressions and wrinkles. Multiple substances are proposed in the field of wrinkle filling and a large part of them act by reactive fibrosis. The low cost and the lack of viscosity of the solute classify hypotonic solutions among the most advantageous products. The solute has the same characteristics as before and is injected by means of an insulin syringe and a very fine needle: 0.3 millimeter.
<U>La préparation à la</U> areffe <U>de tissu graisseux</U> et d'autres tissus mous permet d'obtenir un meilleur pourcentage de prise de greffe. Elle a lieu quelques heures à quelques jours avant la greffe. Un soluté hypotonique ayant une pression osmotique égale ou inférieure à 60 milliosmoles par litre ( idéalement autour de 18 ) est injecté en hypodermique et déclenche une inflammation. La dilatation capillaire consécutive est propice à la greffe de tissu.Les moyens permettant d'obtenir l'osmolarité du soluté sont les même que précédemment .Celle-ci sera toujours supérieure à une milli-osmole. <U> The preparation of the <U> greasy tissue </ U> and other soft tissues results in a better percentage of engraftment. It takes place a few hours to a few days before the transplant. A hypotonic solute with osmotic pressure equal to or less than 60 milliosmoles per liter (ideally around 18) is injected hypodermally and triggers inflammation. The consecutive capillary dilation is conducive to tissue grafting. The means for obtaining the osmolarity of the solute are the same as above. This will always be greater than one milli-osmole.
<U>La destruction</U> des cellules graisseuses comme de leur tissu de soutien nécessite l'injection d'un soluté de faible pression osmotique: de 30 milliosmoles par litre à 1 milliosmole (idéalement autour de 18 milliosmoles) . L'injection se pratique au moyen d'une tubulure disposant d'un compte goutte et d'une aiguille comme décrit cidessus. La destruction est immédiate . Tous les tissus sont accessible à ce mode de destruction qui est maximum au contact de l'aiguille. Ce procédé est d'une grande précision. <U> The destruction </ U> of fat cells as well as their support tissue requires the injection of a low osmotic pressure solute: from 30 milliosmoles per liter to 1 milliosmol (ideally around 18 milliosmoles). The injection is performed by means of a tubing with a dropper and a needle as described above. The destruction is immediate. All tissues are accessible to this mode of destruction which is maximum in contact with the needle. This process is of great precision.
Les indications en cancérologie et en épilation définitives n'ont pas encore fait l'objet d'études hospitalières. -sticité de la,.peau peut être stimulée par irritation des fibres élastiques dermiques grâce à un soluté hypotonique injecté juste sous le derme. La pression osmotique étant comprise entre 30 et 1 milli-osmole par litre ( idéalement 18) Le procédé d'injection est identique à la description ci-dessus: tubulure et aiguille. La peau prend un aspect lisse et la taille des vergétures diminuent. Les micro-nodules cellulitiques situés au même niveau disparaissent.Indications in oncology and final hair removal have not yet been the subject of hospital studies. -stability of the skin can be stimulated by irritation of the dermal elastic fibers thanks to a hypotonic solution injected just below the dermis. The osmotic pressure being between 30 and 1 milli-osmole per liter (ideally 18). The injection method is identical to the description above: tubing and needle. The skin takes on a smooth appearance and the size of the vergetures decreases. Cellulitic micro-nodules at the same level disappear.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9908030A FR2795320B1 (en) | 1999-06-23 | 1999-06-23 | INDICATIONS OF HYPOTONIC SOLUTES AND ANY MODE OF ADMINISTRATION IN AESTHETIC MEDICINE AND CANCEROLOGY |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9908030A FR2795320B1 (en) | 1999-06-23 | 1999-06-23 | INDICATIONS OF HYPOTONIC SOLUTES AND ANY MODE OF ADMINISTRATION IN AESTHETIC MEDICINE AND CANCEROLOGY |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2795320A1 true FR2795320A1 (en) | 2000-12-29 |
| FR2795320B1 FR2795320B1 (en) | 2005-09-02 |
Family
ID=9547214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR9908030A Expired - Fee Related FR2795320B1 (en) | 1999-06-23 | 1999-06-23 | INDICATIONS OF HYPOTONIC SOLUTES AND ANY MODE OF ADMINISTRATION IN AESTHETIC MEDICINE AND CANCEROLOGY |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2795320B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2819189A1 (en) * | 2001-01-10 | 2002-07-12 | Bernstein Veronique | PREPARATION OF AN INJECTABLE HYPO-OSMOLAR COMPOSITION FOR THE TREATMENT OF CELLULITE AND FAT STOCK |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3137624A (en) * | 1962-02-07 | 1964-06-16 | William T Foley | Composition and method for treating defective veins |
| FR2770779A1 (en) * | 1997-11-10 | 1999-05-14 | Bernstein Veronique | Solutions of plasma electrolytes having a lower osmolarity than plasma |
-
1999
- 1999-06-23 FR FR9908030A patent/FR2795320B1/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3137624A (en) * | 1962-02-07 | 1964-06-16 | William T Foley | Composition and method for treating defective veins |
| FR2770779A1 (en) * | 1997-11-10 | 1999-05-14 | Bernstein Veronique | Solutions of plasma electrolytes having a lower osmolarity than plasma |
Non-Patent Citations (2)
| Title |
|---|
| BUSSIEN R ET AL: "THE TUMESCENT TECHNIQUE REVISITED", EUROPEAN JOURNAL OF PLASTIC SURGERY, HEIDELBERG, DE, vol. 19, no. 3, 1996, pages 124 - 131, XP002059321, ISSN: 0930-343X * |
| R.L.GRIER AND ALL.: "Mast cell tumour destruction in dogs by hypotonic solution", JOURNAL OF SMALL ANIMAL PRACTICE, vol. 36, 1995, pages 385 - 388, XP008032096 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2819189A1 (en) * | 2001-01-10 | 2002-07-12 | Bernstein Veronique | PREPARATION OF AN INJECTABLE HYPO-OSMOLAR COMPOSITION FOR THE TREATMENT OF CELLULITE AND FAT STOCK |
| WO2002055094A1 (en) * | 2001-01-10 | 2002-07-18 | Bernstein Veronique | Injectable hypo-osmolar solution |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2795320B1 (en) | 2005-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lin et al. | Strategy for hypertrophic scar therapy: improved delivery of triamcinolone acetonide using mechanically robust tip-concentrated dissolving microneedle array | |
| Yao et al. | Flexible two-layer dissolving and safing microneedle transdermal of neurotoxin: A biocomfortable attempt to treat Rheumatoid Arthritis | |
| CN107349175A (en) | A kind of microneedle patch for loading fatty brown stain agent and preparation method thereof | |
| Xie et al. | Enhanced in vitro efficacy for inhibiting hypertrophic scar by bleomycin-loaded dissolving hyaluronic acid microneedles | |
| Olsson et al. | Revascularization of transplanted pancreatic islets following culture with stimulators of angiogenesis | |
| CN1665561A (en) | Delivers compositions to the microstructure of the skin | |
| EA017682B1 (en) | Polymer and process for obtaining same, pharmaceutical composition in nanoparticulate form, process and kit for preparation thereof and method of treating pathological conditions in humans or animals | |
| CN109310646A (en) | Epinephrine composition for enhanced delivery | |
| KR102175312B1 (en) | Microstructure for transdermal delivery | |
| US11331277B2 (en) | H2O2-responsive nanoparticles and uses thereof | |
| CN108245481A (en) | Microneedle and microneedle patch | |
| Liu et al. | Inflammatory macrophage reprogramming strategy of fucoidan microneedles-mediated ROS-responsive polymers for rheumatoid arthritis | |
| CN114028264A (en) | Microneedle patch for acne removal and repair and preparation method and application thereof | |
| Zhang et al. | Chitosan-based injectable hydrogels with dual glucose sensors for precise control of insulin release and diabetes mellitus therapy | |
| CN114099414A (en) | Microneedle capable of controllably and slowly releasing medicine and preparation method thereof | |
| FR2795320A1 (en) | Hypotonic injectable solutions for esthetic treatment and for use in cancer treatment | |
| Li et al. | Ice-pop making inspired photothermal ultra-swelling microneedles to facilitate loading and intradermal vaccination of tumor antigen | |
| FR2770779A1 (en) | Solutions of plasma electrolytes having a lower osmolarity than plasma | |
| WO2009007660A1 (en) | Liquid or paste compositions intended to provide elements essential for the synthesis and formation of proteoglycans, in particular, for the treatment of cartilage degradation | |
| EP1862161A1 (en) | Injectable pharmaceutical, cosmetic compositions and/or medical devices on the basis of hyaluronic-acid | |
| FR3127688A1 (en) | TOPICAL PHARMACEUTICAL COMPOSITION IN THE FORM OF A GEL COMPRISING AT LEAST AMITRIPTYLINE FOR ITS USE IN THE TREATMENT OF NEUROPATHIC PAIN INDUCED BY A CORONAVIRUS | |
| WO2017103241A1 (en) | Hyaluronic acid composition for penile injections | |
| US9675677B2 (en) | Treatment of Peyronie's disease | |
| TWI271202B (en) | Formula for stimulating biological active substance entering skin or mucous membrane and the application of the same | |
| Verma et al. | Introduction of anatomy of the skin and microneedles as a smart carrier for drug delivery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse | ||
| RN | Application for restoration | ||
| FC | Decision of inpi director general to approve request for restoration | ||
| RN | Application for restoration | ||
| FC | Decision of inpi director general to approve request for restoration | ||
| ST | Notification of lapse |
Effective date: 20120229 |